Use of Highly Active Antiretroviral Therapy in a Cohort of HIV-Seropositive Women
Judith A. Cook, PhD,
Mardge H. Cohen, MD,
Dennis Grey, BA,
Lynn Kirstein, MS,
Jane Burke, MS,
Kathryn Anastos, MD,
Herminia Palacio, MD,
Jean Richardson, DrPH,
Tracey E. Wilson, PhD and
Mary Young, MD
Judith A. Cook, Dennis Grey, and Jane Burke are with the Department of Psychiatry, University of Illinois at Chicago. Mardge H. Cohen is with the Core Center, Cook County Hospital, Chicago. Lynn Kirstein is with the Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Md. Kathryn Anastos is with the Department of Medicine, Montefiore Medical Center, Bronx, NY. Herminia Palacio is with the Division of Population Health and Prevention, San Francisco Department of Public Health, San Francisco, Calif. Jean Richardson is with the Department of Preventive Medicine, University of Southern California, Los Angeles. Tracey E. Wilson is with the Department of Preventive Medicine and Community Health, State University of New York Health Science Center at Brooklyn. Mary Young is with the Department of Medicine, Georgetown University Medical Center, Washington, DC.
Correspondence: Requests for reprints should be sent to Judith A. Cook, PhD, Mental Health Services Research Program, Department of Psychiatry, University of Illinois at Chicago, 104 S Michigan Ave, Suite 900, Chicago, IL 60603 (e-mail: cook{at}ripco.com).
Objectives. This study examined longitudinal trends in use ofhighly active antiretroviral therapy (HAART) among a cohortof HIV-positive participants in the Women's Interagency HIVStudy.
Methods. Beginning in 1994, 1690 HIV-positive women reporteddetailed information about their use of antiretroviral therapyat 6-month study visits. Multivariate logistic and Cox regressionanalyses were used to estimate the likelihood of antiretroviraltherapy and HAART use among women with study visits precedingand following HAART availability.
Results. Before the availability of HAART, the cohort's likelihoodof any antiretroviral therapy use was associated with clinicalindicators (CD4 count, viral load, symptom presence) as wellas behavioral factors (abstaining from drug and alcohol use,participating in clinical trials). After HAART became commerciallyavailable, newly emerging predictors included college education,private insurance, absence of injection drug use history, andnot being African American.
Conclusions. After the penetration of HAART into this cohort,additional differences emerged between HAART users and nonusers.These findings can inform public health efforts to enhance women'saccess to the most effective types of therapy.
This article has been cited by other articles:
D. J. Merenstein, M. F. Schneider, C. Cox, R. Schwartz, K. Weber, E. Robison, M. Gandhi, J. Richardson, and M. W. Plankey Association Between Living With Children and Adherence to Highly Active Antiretroviral Therapy in the Women's Interagency HIV Study
Pediatrics,
April 1, 2008;
121(4):
e787 - e793.
[Abstract][Full Text][PDF]
R. M. Melendez, T. A. Exner, A. A. Ehrhardt, B. Dodge, R. H. Remien, M.-J. Rotheram-Borus, M. Lightfoot, D. Hong, and The National Institute Of Mental Health Healthy Li Health and Health Care Among Male-to-Female Transgender Persons Who Are HIV Positive
Am J Public Health,
June 1, 2006;
96(6):
1034 - 1037.
[Abstract][Full Text][PDF]
J. K. Burke-Miller, J. A. Cook, M. H. Cohen, N. A. Hessol, T. E. Wilson, J. L. Richardson, P. Williams, and S. J. Gange Longitudinal Relationships Between Use of Highly Active Antiretroviral Therapy and Satisfaction With Care Among Women Living With HIV/AIDS
Am J Public Health,
June 1, 2006;
96(6):
1044 - 1051.
[Abstract][Full Text][PDF]
J. G. Feldman, H. Minkoff, M. F. Schneider, S. J. Gange, M. Cohen, D. H. Watts, M. Gandhi, R. S. Mocharnuk, and K. Anastos Association of Cigarette Smoking With HIV Prognosis Among Women in the HAART Era: A Report From the Women's Interagency HIV Study
Am J Public Health,
June 1, 2006;
96(6):
1060 - 1065.
[Abstract][Full Text][PDF]
M. C. Bacon, V. von Wyl, C. Alden, G. Sharp, E. Robison, N. Hessol, S. Gange, Y. Barranday, S. Holman, K. Weber, et al. The Women's Interagency HIV Study: an Observational Cohort Brings Clinical Sciences to the Bench
Clin. Vaccine Immunol.,
September 1, 2005;
12(9):
1013 - 1019.
[Full Text][PDF]
P. N. Halkitis, A. H. Kutnick, and S. Slater The Social Realities of Adherence to Protease Inhibitor Regimens: Substance Use, Health Care and Psychological States
J Health Psychol,
July 1, 2005;
10(4):
545 - 558.
[Abstract][PDF]
J. A. Cook, D. Grey, J. Burke, M. H. Cohen, A. C. Gurtman, J. L. Richardson, T. E. Wilson, M. A. Young, and N. A. Hessol Depressive Symptoms and AIDS-Related Mortality Among a Multisite Cohort of HIV-Positive Women
Am J Public Health,
July 1, 2004;
94(7):
1133 - 1140.
[Abstract][Full Text][PDF]
T. E. Wilson, M. E. Gore, R. Greenblatt, M. Cohen, H. Minkoff, S. Silver, E. Robison, A. Levine, and S. J. Gange Changes in Sexual Behavior Among HIV-Infected Women After Initiation of HAART
Am J Public Health,
July 1, 2004;
94(7):
1141 - 1146.
[Abstract][Full Text][PDF]
M. H. Cohen, J. A. Cook, D. Grey, M. Young, L. H. Hanau, P. Tien, A. M. Levine, and T. E. Wilson Medically Eligible Women Who Do Not Use HAART: The Importance of Abuse, Drug Use, and Race
Am J Public Health,
July 1, 2004;
94(7):
1147 - 1151.
[Abstract][Full Text][PDF]
K. Anastos, Y. Barron, M. H. Cohen, R. M. Greenblatt, H. Minkoff, A. Levine, M. Young, and S. J. Gange The Prognostic Importance of Changes in CD4+ Cell Count and HIV-1 RNA Level in Women after Initiating Highly Active Antiretroviral Therapy
Ann Intern Med,
February 17, 2004;
140(4):
256 - 264.
[Abstract][Full Text][PDF]
D. Greenspan, S.J. Gange, J.A. Phelan, M. Navazesh, M.E.A.F. Alves, L.A. MacPhail, R. Mulligan, and J.S. Greenspan Incidence of Oral Lesions in HIV-1-infected Women: Reduction with HAART
Journal of Dental Research,
February 1, 2004;
83(2):
145 - 150.
[Abstract][Full Text][PDF]